Testing asciminib for children and young adults with a type of leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific type of B-cell leukemia that has a change in the ABL gene (called Philadelphia-positive or ABL-class Ph-like ALL).
- Your leukemia must still be active (detectable) after at least one round of treatment or have come back after treatment.
- If you have had a prior treatment that targets a protein called CD19 (like CAR T-cell therapy), you must still have evidence of CD19 on your leukemia cells after that treatment.
- You must have normal liver and kidney function, as shown by blood tests.
- Your heart function must be normal, as shown by a heart ultrasound (echocardiogram).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding asciminib, a targeted pill, to standard treatment works better for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph+ ALL). It is for those who are older, or who cannot or choose not to have intensive chemotherapy.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This trial tests a pill called asciminib given after a stem cell transplant or CAR T therapy to help prevent relapse in adults with Philadelphia chromosome-positive ALL. It is for people whose cancer is currently in remission.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.